Clarus Therapeutics Holdings, Inc. Warrants
CRXTW
CRXTW was delisted on the 30th of August, 2022.
18 hedge funds and large institutions have $192K invested in Clarus Therapeutics Holdings, Inc. Warrants in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
13% more funds holding
Funds holding: 16 → 18 (+2)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
63% less capital invested
Capital invested by funds: $512K → $192K (-$320K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$16K |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$7.38K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$2.64K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.19K |
| 5 |
Walleye Trading
New York
|
+$1.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$10K |
| 2 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$2.81K |
| 3 |
VF
Virtu Financial
New York
|
-$2K |
| 4 |
HF
HRT Financial
New York
|
-$659 |
CRXTW Hedge Fund Activity: Q2 2022 in Review
18 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) for Q2 2022, worth a combined $192K — down 63% from $512K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CRXTW positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Privium Fund Management, opening a new position worth an estimated $16K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $10K sold.
- 18 institutional investors held Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) as of Q2 2022, up from 16 in Q1 2022.
- Funds reported $192K of Clarus Therapeutics Holdings, Inc. Warrants stock for Q2 2022, down 63% quarter-over-quarter.
- 4 funds opened new Clarus Therapeutics Holdings, Inc. Warrants positions in Q2 2022 and 2 closed out, a net change of +2 holders.
- The largest Clarus Therapeutics Holdings, Inc. Warrants buyer in Q2 2022 was Privium Fund Management, an estimated $16K added.
- The largest Clarus Therapeutics Holdings, Inc. Warrants seller in Q2 2022 was Warberg Asset Management, an estimated $10K sold.
Based on aggregated 13F filings for Q2 2022.